Valeant Pharmaceuticals International, Inc. (VRX) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Aegis Capital Comments on Valeant Pharma (VRX) Following Q1 Results
May 8, 2014 9:46 AM EDTAegis Capital affirms Valeant Pharmaceuticals (NYSE: VRX) at Buy with a price target of $180 following Q1 results. Valeant reported Q1 EPS of $1.76,versus consensus views calling for EPS of $1.72. Revenue for the quarter came in at $1.85 billion, versus $1.04 billion reported last year.
Analyst Ram Selvaraju commented, We have slightly modified... More
